Blue light therapy for hyperbilirubinemia may alter skin microbiome

Blue light phototherapy for hyperbilirubinemia may be associated with short-term changes to the skin and gut microbiome, as well as inflammatory signaling, according to a study published in Pediatric Dermatology.
Based on the limited long-term clinical trials available, the researchers concluded that there is no evidence of a relationship between blue light phototherapy for neonatal hyperbilirubinemia, an underlying cause of jaundice, and an increased risk for future atopic disease and skin cancer. However, the lack of available data highlights a need for future longitudinal studies, according

Machine learning algorithm detects hypertension, diabetes from facial videos

MUNICH — Researchers detected hypertension and type 2 diabetes with high accuracy in as little as 5 seconds using machine learning on spectroscopic facial videos, a potentially scalable screening tool for cardiovascular risk factors. 
Screenings for hypertension and type 2 diabetes, the leading modifiable risk factors for CVD, rely on dedicated clinical encounters or wearable devices, both of which limit population-level coverage, Ryoko Uchida, BPharm, a researcher with the University of Tokyo Hospital, said during a poster presentation at the European Society of Cardiology Congress. 

Higher cardiorespiratory fitness may slow kidney function decline

Increasing levels of cardiorespiratory fitness were linked to slower declines in kidney function, according to study data published in Medicine & Science in Sports & Exercise.
Exercise may help to slow kidney function decline for patients before chronic kidney disease onset, according to Shun Yoshikoshi, PhD, specially appointed assistant professor at the Institute of Health and Sport Sciences at University of Tsukuba in Japan, Keisei Kosaki, PhD, assistant professor at the institute, and colleagues. Thus, the researchers aimed to explore the effect of higher cardiorespiratory fitness

FDA clears reusable insulin patch pump for people with diabetes

The FDA has cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in people with diabetes, Beta Bionics announced.
Mint (Beta Bionics) is a disposable insulin patch pump that can be used for multiple days without recharging. According to a company press release, the pump contains a 200U insulin reservoir and is smaller than other currently available patch pumps. It can be integrated with multiple continuous glucose monitors, including the Dexcom G7, Dexcom G7 15-day and Abbott FreeStyle Libre 3 Plus. The pump can be controlled through an

Prevent cardiometabolic diseases across reproductive lifespan

Healthcare professionals should make cardiometabolic disease prevention a focus for women across the entire reproductive lifespan, according to two presenters at the Association of Diabetes Care & Education Specialists annual meeting.
A woman’s reproductive health can provide clues for future cardiometabolic risk, according to Jacqueline LaManna, PhD, APRN, ANP-BC, BC-ADM, CDCES, FADCES, FAANP, associate professor at University of Central Florida College of Nursing and nurse practitioner in the endocrine specialty clinic at the Florida Department of Health. LaManna and Patricia Davidson,

Emergency presentation of cancer common among older adults

Emergency presentation of cancer is prevalent among older adults in the United States and is linked to poorer outcomes, according to study results.
More than one-quarter of Medicare beneficiaries diagnosed with common types of cancer during a recent 10-year period received their diagnosis after an ED visit.
Individuals diagnosed after emergency presentation had significantly higher risk for death in the following year than those diagnosed in routine settings, including through screening for cancers with recommended tests.
The findings have important implications at the system level to ensure

FDA accepts new drug application for nebulized Tyvaso in IPF

The FDA accepted United Therapeutics’ supplemental new drug application for nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary fibrosis, according to a press release.
“Current FDA-approved treatments for IPF are oral antifibrotic therapies,” Franck Rahaghi, MD, chief medical officer of United Therapeutics, told Healio. “If approved, nebulized Tyvaso (treprostinil) would be the first and only inhaled antifibrotic treatment for IPF, combining direct lung delivery with multi-modal activity across fibrotic, vascular and inflammatory pathways.”

Socioeconomic conditions impact odds for outgrowing food allergy

The odds for food allergy resolution were significantly reduced among Black and Hispanic children vs. white children, according to data published in Annals of Allergy, Asthma & Immunology.
Additionally, having limited health literacy and a lower annual household income negatively impacted a child’s odds for food allergy resolution, according to researchers.
“Several factors associated with food allergy outgrowth are closely linked to socioeconomic conditions, suggesting that socioeconomic circumstances may play a role in the development or recognition of tolerance,” Mahboobeh Mahdavinia,

Closing the colorectal screening gap starts with matching options to patient preference

Clinicians have more colorectal cancer screening options than ever before. The challenge is helping more eligible patients complete them.
Colorectal cancer screening has the power to change patient outcomes by detecting disease earlier and, in some cases, preventing cancer altogether. Yet despite well-established screening recommendations and continued advances in testing, one in four eligible U.S. adults remains unscreened for colorectal cancer.
With cases continuing to rise in the U.S., closing the screening gap is becoming even more urgent. Nearly 159,000 Americans are expected to be

Study links assisted conception with Kawasaki disease risk

Three methods of assisted conception were associated with Kawasaki disease among children aged younger than 5 years, according to data from a Japanese cohort published in JAMA Network Open.
“In 2023, approximately 11.7% of all live births in Japan resulted from assisted reproductive technology (ART), which is substantially higher than the rates in Europe (7.9%) and the U.S. (5.1%),” Sachiko Baba, MD, PhD, of the Osaka Women’s and Children’s Hospital, in Izumi, Japan, and colleagues, wrote. “Given this widespread and increasing use of ART, there is also growing